UK government will not implement generic substitution of medicine; decision welcomed by ABPI and EMIG
In what is clearly a victory for the research-based pharmaceutical industry, the UK government has decided not to progress with plans for the automatic generic substitution of medicines in primary care, Health Minister Lord Howe announced yesterday.
Following a full public consultation, which was announced at the start of the year (The Pharma Letter January 6), the government has now published its response which outlines the reasons why proposals which would have allowed dispensers to replace branded drugs for generic versions when dispensing a prescription will now not be implemented for the National Health Service in England.
Doctors and other frontline health professionals have always based their prescribing decisions on individual assessments of their patients’ clinical circumstances and will continue to do so. Prescribers are free to prescribe branded or generic medicines, and nearly 85% of prescriptions written for patients are already for generic medicines.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze